Exploiting beneficial alloreactive T cells.
Although the T-cell response to allogeneic cells is typically regarded as a detrimental phenomenon responsible for rejection of transplanted allografts and graft-vs.-host disease following haematopoietic stem cell transplantation, beneficial components also exist within the alloreactive population. Alloreactive T cells specific for tumour antigens can contribute to the elimination of malignant cells, and alloantigen-specific regulatory T cells can promote transplant tolerance. The challenge is to separate the good from the bad. We review how the identification, isolation and manipulation of beneficial alloreactive T cells has grown from a greater understanding of the molecular basis of the T-cell alloresponse and how alloaggression could be exploited for immunotherapy.
Barber
L D
LD
The Anthony Nolan Research Institute, Royal Free Hospital, Pond Street, Hampstead, London, UK. l.barber@medsch.ucl.ac.uk
Madrigal
J A
JA
D019264:Adoptive Transfer; D006086:Graft vs Host Disease / Q000209:etiology / Q000276:immunology*; D020350:Graft vs Tumor Effect / Q000276:immunology*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007519:Isoantigens / Q000276:immunology*; D008213:Lymphocyte Activation / Q000276:immunology; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy; D013601:T-Lymphocytes / Q000276:immunology* / Q000637:transplantation; D023001:Transplantation Tolerance / Q000276:immunology; D014184:Transplantation, Homologous
D007519:Isoantigens